Immuneering Corporation (IMRX)
4.18
-0.01 (0.24%)
Upcoming Events
Latest Headlines
Form 8-K Immuneering Corp For: Jun 11
June 15, 2026 4:12 PM - SEC Filing
Immuneering names Andrew Gengos as chief financial officer
June 15, 2026 7:30 AM - StreetInsider
Immuneering Appoints Andrew Gengos as Chief Financial Officer
June 15, 2026 7:30 AM - StreetInsider
Form 4 Immuneering Corp For: Jun 11 Filed by: Schall Thomas J.
June 11, 2026 5:38 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: HAUSMAN DIANA
June 11, 2026 5:33 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: CARPENTER ROBERT J
June 11, 2026 5:30 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: KEATING LAURIE
June 11, 2026 5:26 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: Feinberg Peter
June 11, 2026 5:23 PM - SEC Filing
Form 8-K Immuneering Corp For: Jun 11
June 11, 2026 5:16 PM - SEC Filing
Immuneering doses first patient in phase 3 pancreatic cancer trial
June 11, 2026 7:30 AM - StreetInsider
Immuneering doses first patient in phase 3 pancreatic cancer trial
June 11, 2026 7:30 AM - StreetInsider
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026 7:30 AM - Globe NewsWire
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026 7:30 AM - StreetInsider
Mizuho defends Immuneering Corporation (IMRX), 'recommend being opportunistic on IMRX'
June 2, 2026 6:43 AM - StreetInsider
Form 8-K Immuneering Corp For: Jun 01
June 1, 2026 4:52 PM - SEC Filing
Oppenheimer Reiterates Outperform Rating on Immuneering Corporation (IMRX) Following Data
June 1, 2026 9:59 AM - StreetInsider
Immuneering reports 17.3-month survival data for pancreatic cancer drug
June 1, 2026 7:31 AM - StreetInsider
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
June 1, 2026 7:30 AM - StreetInsider
Immuneering reports 17.3-month survival in pancreatic cancer trial
May 21, 2026 5:02 PM - StreetInsider
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
May 21, 2026 5:00 PM - Globe NewsWire
Form 10-Q Immuneering Corp For: Mar 31
May 15, 2026 7:52 AM - SEC Filing
Form 8-K Immuneering Corp For: May 15
May 15, 2026 7:44 AM - SEC Filing
Immuneering reports Q1 2026 financial results and clinical updates
May 15, 2026 7:35 AM - StreetInsider
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
May 15, 2026 7:35 AM - Globe NewsWire
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
April 21, 2026 4:05 PM - StreetInsider
Form DEFA14A Immuneering Corp
April 20, 2026 4:16 PM - SEC Filing
Form DEF 14A Immuneering Corp For: Apr 20
April 20, 2026 4:10 PM - SEC Filing
Immuneering presents genetic data supporting atebimetinib durability
April 20, 2026 9:01 AM - StreetInsider
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
April 20, 2026 9:00 AM - StreetInsider
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
April 6, 2026 4:05 PM - StreetInsider
Full Article List
